|
|
By Mary Lou Zett, Ph.D., Pharmatech Associates
In Part 2 of this two-part article, we discuss what information is critical to support the sponsor’s argument that the proposed product is biosimilar to the designated reference product, when it is appropriate to do so, and what level of detail it should have for each stage of interaction with the FDA.
|